T
Tessa Cigler
Researcher at Cornell University
Publications - 57
Citations - 1457
Tessa Cigler is an academic researcher from Cornell University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 21, co-authored 55 publications receiving 1162 citations. Previous affiliations of Tessa Cigler include Harvard University & Rockefeller University.
Papers
More filters
Journal ArticleDOI
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
Denise A. Yardley,Robert Weaver,Michelle E. Melisko,Mansoor N. Saleh,Francis P. Arena,Andres Forero,Tessa Cigler,Alison Stopeck,Dennis Citrin,Ira Oliff,Rebecca Bechhold,Randa Loutfi,Agustin A. Garcia,Scott Cruickshank,Elizabeth Crowley,Jennifer Green,Thomas Hawthorne,Michael Yellin,Thomas A. Davis,Linda T. Vahdat +19 more
TL;DR: Glembatumumab vedotin was well tolerated as compared with IC chemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia), and activity may be enhanced in patients with gpNMB-overexpressing tumors and/or TNBC.
Journal ArticleDOI
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
Hope S. Rugo,P Klein,Susan A. Melin,Sara A. Hurvitz,Michelle E. Melisko,Anne Moore,Glen D. Park,Jules T. Mitchel,Erika Bågeman,Ralph B. D'Agostino,Elizabeth S. Ver Hoeve,Laura J. Esserman,Tessa Cigler +12 more
TL;DR: Among women undergoing non–anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy, and quality of life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group.
Journal ArticleDOI
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
Nancy Chan,Amy D. Willis,Naomi Kornhauser,Maureen M. Ward,Sharrell Lee,Eleni Nackos,Bo Ri Seo,Ellen Chuang,Tessa Cigler,Anne Moore,Diana Donovan,M Cobham,Veronica Fitzpatrick,Sarah E. Schneider,Alysia Wiener,Jessica Guillaume-Abraham,Elnaz Aljom,Richard Zelkowitz,J. David Warren,Maureen E. Lane,Claudia Fischbach,Vivek Mittal,Linda T. Vahdat +22 more
TL;DR: Tetrathiomolybdate is safe, well tolerated, and affects copper-dependent components of the tumor microenvironment, and biomarker-driven clinical trials in high risk for patients with recurrent breast cancer are warranted.
Journal ArticleDOI
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo,Paul Frankel,Banu Arun,Cynthia X. Ma,Agustin A. Garcia,Tessa Cigler,Leah Cream,Harold A. Harvey,Joseph A. Sparano,Rita Nanda,Helen K. Chew,Timothy J. Moynihan,Linda T. Vahdat,Matthew P. Goetz,Jan H. Beumer,Arti Hurria,Joanne E. Mortimer,Richard Piekarz,Sharon Sand,Josef Herzog,Lily R. Van Tongeren,Katherine V. Ferry-Galow,Alice P. Chen,Christopher Ruel,Edward M. Newman,David R. Gandara,Jeffrey N. Weitzel +26 more
TL;DR: Safety and efficacy are encouraging with veliparib alone and in combination with carboplatin in BRCA-associated MBC and higher baseline PAR was associated with clinical benefit.
Journal ArticleDOI
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Noah D. Kauff,Nandita Mitra,Mark E. Robson,Karen Hurley,Shaokun Chuai,Deborah J. Goldfrank,E. Wadsworth,Johanna Lee,Tessa Cigler,Patrick I. Borgen,Larry Norton,Richard R. Barakat,Kenneth Offit +12 more
TL;DR: The results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer.